Device Trauma Emergency, Injury, Surgery

Strattice Reconstructive Tissue Matrix Bps

Payments companies reported to CMS as associated with Strattice Reconstructive Tissue Matrix Bps. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$3.2Massociated payments (2023-2025)
1,847clinicians with associated payments
2companies reporting

By year

2023 $1.4M
2024 $1.4M
2025 $366K

Payments reported as associated with Strattice Reconstructive Tissue Matrix Bps, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Plastic Surgery $1.3M
Surgery $904K
Plastic and Reconstructive Surgery $351K
Surgical Critical Care $141K
Physician Assistant $69K
Optometrist $48K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Strattice Reconstructive Tissue Matrix Bps

These are the largest totals companies reported as associated with Strattice Reconstructive Tissue Matrix Bps. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Robert Martindale Portland, OR Surgery $164,862.89
Casey Thomas Las Vegas, NV Surgical Critical Care $125,807.02
Omar Guerra Saint Louis, MO Surgery $99,913.09
Scot Glasberg New York, NY Plastic Surgery $86,207.03
Vedra Augenstein Charlotte, NC Surgery $86,187.00
Maurice Nahabedian Mc Lean, VA Plastic and Reconstructive Surgery $77,262.78
Parag Bhanot Washington, DC Surgery $70,588.18
Michael Edwards Las Vegas, NV Plastic Surgery $68,579.04
Nicholas Clavin Charlotte, NC Plastic Surgery $65,816.27
Vahagn Nikolian Portland, OR Surgery $53,784.36

Prescribed Strattice Reconstructive Tissue Matrix Bps?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.